STOCK TITAN

Eton Pharmaceutcials (ETON) Stock News

ETON NASDAQ

Eton Pharmaceuticals develops and commercializes treatments for rare diseases, with commercial products that include KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. Company news commonly covers FDA approvals, product launches, licensing of U.S. commercialization rights, specialty pharmacy distribution and Eton Cares patient-support programs.

Updates also address financial results, product-sales trends, late-stage product candidates and clinical work for rare-disease therapies. Pipeline references include Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector, with ET-700 described as an extended-release zinc acetate formulation for Wilson disease.

Rhea-AI Summary

Eton Pharmaceuticals (ETON) reported third-quarter 2026 revenue of $57.9 million, up 158% from the prior-year quarter, and raised its annual outlook. Eton now expects 2026 revenue above $175 million, versus above $145 million previously, and an adjusted EBITDA margin of at least 40%, versus at least 35%. Adjusted EBITDA, an earnings measure excluding specified expenses, reached $28.5 million, or 49% of revenue, versus $2.9 million and 13% a year earlier.

GAAP net income was $35.2 million, or $1.06 per diluted share, versus a $1.9 million loss. Earnings included a one-time tax benefit; non-GAAP diluted earnings were $0.50 per share. Cash was $55.6 million at September 30. Eton licensed LIBERVANT, targeting an April 2027 launch subject to FDA approval, and advanced several development programs. ET-700's pilot study showed fewer treatment-related adverse events but less reduction in hepatic copper uptake than GALZIN.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.75%
Tags
-
Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) reported preliminary ET-700 pilot results showing fewer treatment-related adverse events but less copper-uptake inhibition than GALZIN. The four-week randomized study tested the investigational extended-release zinc acetate in healthy volunteers. Treatment-related adverse events affected 1 of 12 ET-700 participants versus 8 of 12 receiving GALZIN and 3 of 12 receiving placebo; no serious adverse events occurred.

In the primary analysis of 29 participants meeting protocol criteria, hepatic copper uptake decreased 12% with ET-700 and 46% with GALZIN, versus an 11% increase with placebo. The supportive 35-participant analysis showed reductions of 18% and 58%, respectively, versus an 11% placebo increase; GALZIN had a greater effect (p=0.023). These preliminary findings do not establish efficacy in Wilson disease patients or long-term comparative safety. Eton plans additional study arms testing faster-release formulations in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.75%
Tags
none
-
Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) will present at the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026. Members of its executive leadership team are scheduled to present from 3:00–3:25 PM GMT / 10:00–10:25 AM EST. A webcast will be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
none
Rhea-AI Summary

Aquestive Therapeutics (NASDAQ: AQST) reported third-quarter 2026 revenue of $7.6 million, down 41% from the same period a year earlier. Net loss widened to $16.5 million from $15.4 million, while basic and diluted loss per share narrowed to $0.13 from $0.14. Cash and cash equivalents were $90.3 million at September 30.

The FDA accepted the Anaphylm resubmission as a complete Class 2 response, setting a March 16, 2027 review goal date. Aquestive expects a Canadian submission in Q4 2026 and plans an EU filing in Q1 2027. In October, it granted Eton exclusive U.S. Libervant commercialization rights for $10 million upfront, potential milestones and royalties, retaining exclusive manufacturing under a 20-year agreement. Full-year guidance remains unchanged at $46–$50 million revenue and a non-GAAP adjusted EBITDA loss of $35 million to $30 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) licensed Baylor College of Medicine patent rights and launched ET-900 to evaluate mecasermin for infantile and epileptic spasms. Mecasermin is the active ingredient in INCRELEX, which Eton markets in the United States. Eton retains commercial rights to ET-900.

In an animal model, recombinant human insulin-like growth factor 1 (IGF-1) reduced daily spasm counts by approximately 50% and eliminated spasms in 20% of treated animals. A research Investigational New Drug application has been submitted for a University of Chicago-sponsored Phase 2 study in children with refractory epileptic spasms. The study is expected to enroll up to 20 patients ages 2–18 years across three sites, with initial enrollment and dosing targeted for Q1 2027. Mecasermin is not FDA-approved for these uses, and safety and efficacy for them have not been established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
Rhea-AI Summary

Eton Pharmaceuticals (ETON) will report its third quarter 2026 financial results on November 5, 2026, with a management call that afternoon. The conference call and live audio webcast will begin at 4:30 p.m. ET. Management will take live and emailed investor questions. A webcast archive will be available on Eton’s website approximately two hours after the event ends and for 30 days thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
earnings date
Rhea-AI Summary

Eton Pharmaceuticals (ETON) entered exclusive U.S. licensing and supply agreements with Aquestive Therapeutics (AQST) for LIBERVANT, a seizure-cluster treatment.

The agreements cover the United States and its territories. Eton anticipates commercial availability in April 2027, subject to final FDA approval, and plans a dedicated neurology team. LIBERVANT, a diazepam film placed inside the cheek, has tentative approval for patients with epilepsy ages 2 to 5 and 12 and above. Full approval for ages 12 and above is expected to become possible after VALTOCO’s orphan drug exclusivity expires on January 10, 2027.

An application to add ages 6 to 11 is under FDA review, with a March 29, 2027 target action date; approval would expand the potential label to ages 6 and older. LIBERVANT has Orphan Drug Designation and issued patent protection extending into 2038, with additional patent applications pending.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary

Eton Pharmaceuticals (ETON) launched IMPAVIDO (miltefosine) capsules in the United States under exclusive commercialization rights. The treatment is indicated for certain forms of visceral, cutaneous and mucosal leishmaniasis in patients aged 12 or older who weigh at least 30 kg. Eton has added IMPAVIDO to its patient support program, including a $0 co-pay for eligible commercially insured patients and expanded patient assistance.

Anovo Specialty Pharmacy handles centralized distribution, hospital consignment access and coordination of urgent requests. IMPAVIDO carries a boxed warning for embryo-fetal toxicity and is contraindicated during pregnancy. Its effectiveness against Leishmania species outside those evaluated has not been established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.60%
Tags
none
-
Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) announced that members of its executive leadership team will participate in 1x1 investor meetings at the 2026 Wells Fargo Healthcare Conference in Boston, MA. The meetings are scheduled for September 9, 2026, during the conference running from September 8–10, 2026. Institutional investors interested in scheduling a 1x1 meeting are instructed to contact their Wells Fargo institutional sales representative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) reported record Q2 2026 net revenue of $37.6 million, up 99% year-over-year, driven by HEMANGEOL and broad portfolio growth. GAAP diluted EPS was $0.35, non-GAAP diluted EPS $0.43, EBITDA $14.1 million, and Adjusted EBITDA $16.2 million, or 43% of revenue.

The company raised 2026 guidance, now expecting revenue to exceed $145 million and Adjusted EBITDA margin of at least 35%. Eton relaunched HEMANGEOL with about 95% patient conversion, licensed late-stage infantile hemangioma candidate ASN-001, submitted a KHINDIVI label-expansion PAS, obtained FDA Fast Track for AMGLIDIA, and acquired U.S. rights to orphan drug IMPAVIDO. Cash and equivalents were $26.8 million as of June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.26%
Tags

FAQ

What is the current stock price of Eton Pharmaceutcials (ETON)?

Eton Pharmaceutcials (ETON) last closed at $60.85.

What is the market cap of Eton Pharmaceutcials (ETON)?

The market cap of Eton Pharmaceutcials (ETON) is approximately $1.8B.